A Two-part Phase 1 Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3862995B Following Single Ascending Doses in Healthy Participants and Repeat Doses in Participants With Chronic Obstructive Pulmonary Disease
Latest Information Update: 02 Jun 2026
At a glance
- Drugs GSK-3862995B (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GSK
Most Recent Events
- 29 May 2026 Planned End Date changed from 31 Mar 2027 to 17 Dec 2026.
- 29 May 2026 Planned primary completion date changed from 31 Mar 2027 to 17 Dec 2026.
- 29 May 2026 Status changed from recruiting to active, no longer recruiting.